{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-025613","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2022-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.992375+00:00","generated_at":"2026-06-21T14:13:34.043142+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cyclerion board rejects unsolicited CEO-led asset purchase proposal","bullets":["Unsolicited proposal received Nov 20, 2022 from group including CEO to purchase certain assets.","Independent board unanimously concluded proposal is not in the best interest of the Company.","Board consulted legal and financial advisors prior to reaching its decision.","Company will not make further statements on M&A activity unless deemed appropriate or necessary."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-025613","json":"https://secwatch.observer/filing/0000950170-22-025613.json","markdown":"https://secwatch.observer/filing/0000950170-22-025613.md","text":"https://secwatch.observer/filing/0000950170-22-025613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022025613/0000950170-22-025613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022025613/cycn-20221122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T14:13:34.043142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}